Abstracts tagged "Economics"

Abstract Number: 1759 • 2017 ACR/ARHP Annual Meeting
Economic Evaluation of Rituximab Versus Azathioprine for Maintenance Treatment of ANCA-Associated Vasculitis. a Prospective, Multicenter Study
Annalisa Montante¹, Alicia Le Bras², Benjamin Terrier³, Pascal Cohen³, Xavier Puéchal⁴, Alexandre Karras⁵, Philippe Ravaud⁶, Loïc Guillevin⁷ and Isabelle Durand-Zaleski⁸, ¹UNITÉ DE RECHERCHE ECONOMIQUE, UNIVERSITE PARIS DESCARTES, PARIS, France, ²UNITE DE RECHERCHE ECONOMIQUE, UNIVERSITE PARIS DESCARTES, PARIS, France, ³Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ⁴Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, ⁵Nephrology, HEGP, Paris, France, ⁶Hôpital Hôtel Dieu, Paris, France, ⁷Internal medicine, Cochin University Hospital, paris, France, ⁸UNITE DE RECHERCHE ECONOMIQUE, UNIVERSITE DE PARIS-CRETEIL, PARIS, France
Background/Purpose: Rituximab was proven to be superior to azathioprine as maintenance therapy for ANCA-associated vasculitides (AAVs) at month 28 of MAINRITSAN-1–trial follow-up. Because of rituximab’s…
Abstract Number: 113 • 2016 ACR/ARHP Annual Meeting
Online Consultation for Chinese Patients with Rheumatic Diseases Based on Smart System of Disease Management (SSDM) Mobile Tools: A Study of Medical Economics
Fei Xiao¹, Xiangyuan Liu², Zhijun Li³, Tong Xie⁴, Xinwang Duan⁵, Huiqiong Zhou⁶, Yanhong Huang⁷, Yi Zheng⁸, Hua Wei⁹, Hongzhi Wang¹⁰, Rong Mu¹¹, Hui Xiao¹, Yuhua Jia¹, Yonggang Zhao¹, Yuan Liu¹ and Fengchun Zhang¹², ¹Gothic Internet Technology Corporation, Shanghai, China, ²Department of Rheumatology and Immunology, Peking University Third hospital, Bei jing, China, ³The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ⁴Affiliated hospital of Guangdong medical University, Zhanjiang, China, ⁵Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁶The First Affiliated Hospital of PLA General Hospital, Beijing, China, ⁷Beijing Jishuitan Hospital, Beijing, China, ⁸8 Gongren Tiyuchang Nanlu, Cha, Beijing Chao-Yang Hospital, Beijing, China, ⁹No 98,Nantong West Rd,Yangzhou, Northern Jiangsu People's Hospital, Yangzhou, China, ¹⁰The First Hospital of Jiaxing, Jiaxing, China, ¹¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ¹²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Background/Purpose: China does not have primary medical care and referral system. Patients can choose any hospital or any doctor they like to seek medical care.…
Abstract Number: 228 • 2016 ACR/ARHP Annual Meeting
Sick Leave and Disability Pension in Working-Age Gout Patients before and after Diagnosis – a Population Based Case-Control Study
Valgerdur R Sigurdardottir¹, Lennart TH Jacobsson², Panagiota Drivelegka², Anna Svärd^1,3 and Mats Dehlin², ¹Rheumatology Clinic, Falun Hospital, SE-791 82 Falun, Sweden, Falun, Sweden, ²Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ³Center for Clinical Research Dalarna, Falun, Sweden
Background/Purpose: Gout is the most common form of inflammatory arthritis with a prevalence of 1.5% in our area in the age group 50-59 years. Gout…
Abstract Number: 1237 • 2016 ACR/ARHP Annual Meeting
The Economic Burden of Dermatomyositis and Polymyositis in the US
J. Bradford Rice¹, Alan White¹, Philip Galebach¹, Andrea Lopez¹, Patricia Schepman², Breanna Popelar³, Michael Philbin⁴ and Elaine Boing², ¹Analysis Group, Inc., Boston, MA, ²Affiliated with Mallinckrodt Pharmaceuticals at the time this study was conducted, Hazelwood, MO, ³Xcenda, L.L.C., Palm Harbor, FL, ⁴Mallinckrodt Pharmaceuticals, Hazelwood, MO
Background/Purpose: Dermatomyositis and polymyositis (DM/PM) are inflammatory myopathies that can lead to persistent muscle weakness and disability. Although significant healthcare resource utilization (HCRU) and work…
Abstract Number: 1243 • 2016 ACR/ARHP Annual Meeting
Validity of the Short Form 6D Utility Measure in Early Axial Spondyloarthritis
Cécile Gaujoux-Viala¹, Laure Gossec², Christel Castelli³, Cédric Lukas⁴, Françoise Barchechath-Flaisler⁵, Jean-Pierre Daures⁶ and Maxime Dougados⁷, ¹Rheumatology Department, University Hospital of Nîmes and EA2415, Montpellier University, Nîmes, France, ²Paris 06 University and AP-HP, Hôpital Pitié Salpêtrière, Paris, France, ³BESPIM, Nîmes University Hospital and EA2415, Nîmes, France, ⁴Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁵Nîmes University Hospital, Rheumatology Department, Nimes, France, ⁶EA2415, Nîmes, France, ⁷Paris Descartes University, Paris, France
Background/Purpose: The quantification of health improvements is essential, notably in the current context of increasingly expensive therapies and more and more limited resources. Preference-based measures…
Abstract Number: 1607 • 2016 ACR/ARHP Annual Meeting
The Development of a New Anti–Interleukin 6 Blocker for Rheumatoid Arthritis Patients
Alan Glicklich¹, Paul Grayson¹, Christophe Blanchetot², Qing Zhou³ and Anke Kretz-Rommel¹, ¹Bird Rock Bio, Inc, La Jolla, CA, ²Argenx, Ghent, Belgium, ³Genor BioPharma, Shanghai, China
Background/Purpose: While interleukin-6 (IL-6) blockade with monoclonal antibodies is an established, clinically validated mechanism for the treatment of rheumatoid arthritis (RA), the need for significant…
Abstract Number: 2252 • 2016 ACR/ARHP Annual Meeting
Estimated Cost of SLE Hospitalizations
Kayla Neville¹, James Miceli¹, Jianhua Li², Samantha Nguyen³, Teja Kapoor³ and Anca Askanase³, ¹Rheumatology, Columbia University Medical Center, New York, NY, ²Department of Biomedical Informatics, Columbia University Medical Center, New York, NY, ³Medicine, Division of Rheumatology, Columbia University Medical Center, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) treatment comes at a high price, with both direct costs related to healthcare resource utilization and indirect ones related to…
Abstract Number: 2356 • 2015 ACR/ARHP Annual Meeting
Major Cardiovascular Events in Gout Patients with Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating on Allopurinol or Febuxostat (Uloric)
JoAnne Foody¹, Robin Turpin², Beni Tidwell³ and Kathy Schulman⁴, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Medical Affairs, Takeda Pharmaceuticals International, Deerfield, IL, ³ORS, Shrewsbury, MA, ⁴Outcomes Research Solutions, Inc., Waltham, MA
Background/Purpose: Xanthine oxidase inhibitors (XOI) reduce both urate levels and oxidative stress in the vasculature, both of which are cardiovascular disease (CVD) risk factors. However,…
Abstract Number: 2473 • 2015 ACR/ARHP Annual Meeting
Psycho-Socio-Economic Burdens of Childhood Onset Rheumatic Diseases on Families
Sook Fun Hoh¹, Manasita Tanya², Justin Hung Tiong Tan², Lena Das^2,3 and Thaschawee Arkachaisri², ¹Nursing, KK Women's and Children's Hospital, Singapore, Singapore, ²Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ³Dept of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Rheumatic diseases (RD) in children, being complex and chronic in nature, do not only pose physical insult to the affected child, but also psychological…
Abstract Number: 113 • 2015 ACR/ARHP Annual Meeting
Longitudinal, Incremental Direct Medical Costs of Giant Cell Arteritis for the First Five Years Following Diagnosis: A General Population-Based Cohort Study
Natalie McCormick¹, Carlo Marra² and J Antonio Avina-Zubieta³, ¹Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Pharm Sciences, Univ of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Giant cell arteritis (GCA) is the most common form of adult vasculitis, but estimates of the healthcare costs of GCA are extremely scarce. We…
Abstract Number: 123 • 2015 ACR/ARHP Annual Meeting
An Economic Evaluation of Tofacitinib (Xeljanz) Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the US
Lindsay Claxton¹, Matthew Taylor¹, Michelle Jenks¹, Gene Wallenstein², Alan Mendelsohn³, Jeffrey Bourret³, Amitabh Singh³ and Robert Gerber², ¹York Health Economics Consortium, University of York, York, United Kingdom, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). An economic model was developed to evaluate the treatment…
Abstract Number: 144 • 2015 ACR/ARHP Annual Meeting
One-Year Costs Following Switching Versus Dose-Escalation Among Prevalent Tumor Necrosis Factor Inhibitors Used for Rheumatoid Arthritis
Tao Gu¹, Derek Tang², Gaurav Deshpande¹, Debra F Eisenberg¹ and David J. Harrison³, ¹HealthCore, Wilmington, DE, ²Amgen, Inc., Thousand Oaks, CA, ³Amgen Inc., Thousand Oaks, CA
Background/Purpose: Switching a biologic treatment or escalating biologic doses are common approaches used upon biologic treatment failure. The objective of this study was to estimate…
Abstract Number: 145 • 2015 ACR/ARHP Annual Meeting
Economic Burden of Switching to an Anti-Tumor Necrosis Factor (anti-TNF) Versus a Non-Tumor Necrosis Factor (non-TNF) Biologic Therapy Among Patients with Rheumatoid Arthritis
Zheng-Yi Zhou¹, Jenny Griffith², Arijit Ganguli², Ella Xiaoyan Du¹ and Keith Betts¹, ¹Analysis Group, Inc., Boston, MA, ²AbbVie Inc., North Chicago, IL
Background/Purpose: Real world studies comparing the healthcare utilization of anti-TNFs vs. non-TNFs as the next alternative after the failure of the first anti-TNF are scarce.…
Abstract Number: 555 • 2015 ACR/ARHP Annual Meeting
Outcomes Associated with Non-Medical Switching/Discontinuation of Anti-TNF Inhibitors Among Patients with Rheumatoid Arthritis
Douglas C. Wolf¹, Martha Skup², Hongbo Yang³, Elizabeth Faust³, Jenny Griffith², Jingdong Chao² and Mark Lebwohl⁴, ¹Atlanta Gastroenterology Associates, Atlanta, GA, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA, ⁴Mount Sinai Medical Center, New York, NY
Background/Purpose: Patients with RA are often treated with anti-tumor necrosis factor (TNF) agents. However, patients with a stable response to anti-TNF therapy may discontinue or…
Abstract Number: 598 • 2015 ACR/ARHP Annual Meeting
Economic Impact of Decreasing Adalimumab and Etanercept Doses and Drug Monitoring in Patients with Rheumatoid Arthritis in Clinical Remission: Preliminary Study from a Local Biologics Unit
José Rosas¹, Francisca Llinares-Tello², José Miguel Senabre¹, Gregorio Santos-Soler¹, Esteban Salas-Heredia¹, Xabier Barber³, Ana Pons⁴, Catalina Cano⁴, Marisa Lorente⁵ and Juan Molina⁶, ¹Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ²Clinical Analysis, Hospital Marina Baixa, Clinical Analysis, Villajoyosa, Spain, ³Centro de Investigación Operativa, Miguel Hernández University, Elche, Spain, ⁴Hospital Marina Baixa, Nursing, Villajoyosa, Spain, ⁵Marina Baixa Hospital, Nursing, Villajoyosa, Spain, ⁶Hospital Marina Baixa, Clinical Analysis, Villajoyosa, Spain
Background/Purpose: To evaluate the economic impact of adalimumab (ADL) and etanercept (ETN) dose reduction (by decreasing treatment frequency) and drug monitoring in patients with rheumatoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].